P Schnider
Overview
Explore the profile of P Schnider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
454
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malherbe P, Knoflach F, Hernandez M, Hoffmann T, Schnider P, Porter R, et al.
Br J Pharmacol
. 2010 Nov;
162(4):929-46.
PMID: 21039418
Background And Purpose: Clinical results of osanetant and talnetant (selective-NK₃ antagonists) indicate that blocking the NK₃ receptor could be beneficial for the treatment of schizophrenia. The objective of this study...
2.
Kranz G, Sycha T, Voller B, Kranz G, Schnider P, Auff E
Neurology
. 2008 Jan;
70(2):133-6.
PMID: 18180443
Background: Complete secondary therapy failure due to antibodies against botulinum toxin A (BoNT/A-ABs) may raise extensive treatment difficulties. We tested whether neutralizing BoNT/A-ABs can be detected in dystonic patients with...
3.
Schnider P, Moraru E, Kittler H, Voller B, Kranz G, Auff E
Wien Klin Wochenschr
. 2004 Oct;
113 Suppl 4:36-41.
PMID: 15506051
Introduction: Botulinum A toxin (BTX-A) acts primarily at peripheral cholinergic synapses, inhibiting the release of acetylcholine. Initially it has been used to block the neuromuscular junction in focal dystonic and...
4.
Voller B, Foldy D, Hefter H, Auff E, Schnider P
Wien Klin Wochenschr
. 2004 Oct;
113 Suppl 4:25-9.
PMID: 15506049
Spastic drop foot can be managed by physical measures, local pharmacological agents, oral anti-spastic drugs and surgical procedures. Recent studies have documented the clear effect of botulinum toxin type A...
5.
Auff E, Poewe W, Schnider P, Wissel J
Wien Klin Wochenschr
. 2004 Oct;
113 Suppl 4:1.
PMID: 15506043
No abstract available.
6.
Sycha T, Graninger M, Auff E, Schnider P
Eur J Clin Invest
. 2004 Apr;
34(4):312-3.
PMID: 15086364
No abstract available.
7.
Naumann M, Eberhardt B, Laskawi R, Porta M, Schnider P, Sostak P, et al.
J Neurol
. 2004 Mar;
251 Suppl 1:I39-40.
PMID: 14991343
No abstract available.
8.
Sycha T, Kranz G, Auff E, Schnider P
J Neurol
. 2004 Mar;
251 Suppl 1:I19-30.
PMID: 14991339
Background: Botulinum neurotoxin (BoNT) is used to treat various neurological disorders associated with pathologically increased muscle tone. Botulinum toxin inhibits the release of the neurotransmitter acetylcholine at the neuromuscular junction...
9.
Voller B, Sycha T, Gustorff B, Schmetterer L, Lehr S, Eichler H, et al.
Neurology
. 2003 Oct;
61(7):940-4.
PMID: 14557564
Objective: Botulinum toxin type A (BTXA) is used to treat neurologic disorders associated with increased muscle tone. Its use is often associated with pain relief. Methods: A possible direct analgesic...
10.
Moraru E, Auff E, Schnider P
Curr Probl Dermatol
. 2002 Dec;
30:156-69.
PMID: 12471710
No abstract available.